Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement grants made March 31, 2026: 72,000 stock options were awarded to four new non‑executive employees under the 2024 Inducement Equity Incentive Plan.

Each option has an exercise price of $32.46 (closing price on the grant date) and vests 25% after one year, then 1/48th monthly thereafter, subject to continued service, granted in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – EWTX

+5.21%

+5.21% Session close to close

In the Apr 1 session, EWTX gained 5.21%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Edg...

Analysis

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with Edgewise’s position near its 52-week high of $32.80 and above its 200-day MA of $20.54. However, past trading shows that routine items like inducement grants and insider-related equity activity have not driven lasting trends compared with major clinical updates. Investors have also seen recent insider sales in regulatory filings, which can temper enthusiasm and contribute to volatility as initial buying interest normalizes.

Key Figures

Inducement option shares: 72,000 shares Number of employees: 4 employees Option exercise price: $32.46 per share +3 more

6 metrics

Inducement option shares 72,000 shares Options granted to 4 new non-executive employees on March 31, 2026

Number of employees 4 employees Recipients of inducement stock options

Option exercise price $32.46 per share Exercise price equal to closing price on March 31, 2026 grant date

Initial vesting tranche 25% of shares Vests on one-year anniversary of each employee’s start date

Ongoing vesting rate 1/48th monthly Monthly vesting after first year, subject to continued service

Listing rule reference Nasdaq Rule 5635(c)(4) Basis for inducement grants outside shareholder-approved plan

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Clinical data update	Positive	+2.2%	Long-term Becker muscular dystrophy data showing sustained functional stabilization and safety.
Mar 04	Conference presentation	Positive	+0.2%	Announcement of upcoming Leerink Global Healthcare Conference presentation and webcast access.
Mar 03	Conference data preview	Positive	-3.0%	Planned presentations on sevasemten and Becker muscular dystrophy data at MDA conference.
Mar 02	Inducement grants	Neutral	-2.4%	Inducement stock options for new hires under 2024 Inducement Equity Incentive Plan.
Feb 26	Earnings and pipeline	Positive	-1.5%	Q4 and 2025 results with strong cash and multiple near-term clinical catalysts outlined.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows stronger positive price reactions to substantive clinical and data updates, while conference announcements, financial results, and routine equity-related items (like inducement grants) have tended to see modest or negative next-day moves.

Recent Company History

Over the past several months, Edgewise has highlighted pipeline and financial progress alongside routine corporate actions. A Mar 10, 2026 Becker muscular dystrophy update with 3.5-year stabilization data saw a positive 2.23% move. Conference and presentation notices on Mar 3–4, 2026 generated small, mixed reactions. Earlier on Mar 2, 2026, similar inducement grants coincided with a -2.43% move. Fourth quarter and full-year 2025 earnings on Feb 26, 2026 brought a -1.53% reaction despite strong cash and pipeline milestones. Today’s inducement awards fit into this pattern of ongoing hiring and equity-based compensation activity.

Key Terms

inducement stock options, equity incentive plan, nasdaq listing rule 5635(c)(4)

3 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 72,000 shares..."

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

equity incentive plan financial

"pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan")."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

nasdaq listing rule 5635(c)(4) regulatory

"granted as inducements material to these employees... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

Each inducement stock option has an exercise price of $32.46 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to edgewisetx.com or follow us on LinkedIn and X.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302730770.html

SOURCE Edgewise Therapeutics

FAQ

How many inducement stock options did Edgewise (EWTX) grant on March 31, 2026?

Edgewise granted 72,000 inducement stock options to four new non‑executive employees. According to the company, the awards were made under the 2024 Inducement Equity Incentive Plan as inducements to join the company.

What was the exercise price of the Edgewise (EWTX) inducement options granted March 31, 2026?

Each inducement option has an exercise price of $32.46 per share, equal to the closing price on the grant date. According to the company, that price matches the market close used for the grant.

What is the vesting schedule for the inducement options Edgewise (EWTX) granted to new employees?

Vesting is 25% on the one‑year anniversary, then an additional 1/48th each month thereafter, subject to continued service. According to the company, this standard vesting aligns retention incentives for new hires.

Under which plan were Edgewise (EWTX) inducement grants issued on March 31, 2026?

The awards were issued under the 2024 Inducement Equity Incentive Plan. According to the company, the grants comply with Nasdaq Listing Rule 5635(c)(4) as inducements for new employees.

Who received the inducement grants from Edgewise (EWTX) and why were they granted?

Four new non‑executive employees received the inducement options as hiring incentives. According to the company, the grants were material inducements to commence employment under Nasdaq rules.